Sexually transmitted infections and use of contraceptives in women living with HIV in Denmark: the SHADE cohort

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Sexually transmitted infections and use of contraceptives in women living with HIV in Denmark : the SHADE cohort. / Thorsteinsson, Kristina; Ladelund, Steen; Storgaard, Merete; Rønsholt, Frederikke Falkencrone; Johansen, Isik Somuncu; Pedersen, Gitte; Nielsen, Lars Nørregård; Bonde, Jesper; Westh, Henrik; Obel, Niels; Katzenstein, Terese L; Lebech, Anne-Mette.

I: B M C Infectious Diseases, Bind 16, 81, 2016.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Thorsteinsson, K, Ladelund, S, Storgaard, M, Rønsholt, FF, Johansen, IS, Pedersen, G, Nielsen, LN, Bonde, J, Westh, H, Obel, N, Katzenstein, TL & Lebech, A-M 2016, 'Sexually transmitted infections and use of contraceptives in women living with HIV in Denmark: the SHADE cohort', B M C Infectious Diseases, bind 16, 81. https://doi.org/10.1186/s12879-016-1412-7

APA

Thorsteinsson, K., Ladelund, S., Storgaard, M., Rønsholt, F. F., Johansen, I. S., Pedersen, G., Nielsen, L. N., Bonde, J., Westh, H., Obel, N., Katzenstein, T. L., & Lebech, A-M. (2016). Sexually transmitted infections and use of contraceptives in women living with HIV in Denmark: the SHADE cohort. B M C Infectious Diseases, 16, [81]. https://doi.org/10.1186/s12879-016-1412-7

Vancouver

Thorsteinsson K, Ladelund S, Storgaard M, Rønsholt FF, Johansen IS, Pedersen G o.a. Sexually transmitted infections and use of contraceptives in women living with HIV in Denmark: the SHADE cohort. B M C Infectious Diseases. 2016;16. 81. https://doi.org/10.1186/s12879-016-1412-7

Author

Thorsteinsson, Kristina ; Ladelund, Steen ; Storgaard, Merete ; Rønsholt, Frederikke Falkencrone ; Johansen, Isik Somuncu ; Pedersen, Gitte ; Nielsen, Lars Nørregård ; Bonde, Jesper ; Westh, Henrik ; Obel, Niels ; Katzenstein, Terese L ; Lebech, Anne-Mette. / Sexually transmitted infections and use of contraceptives in women living with HIV in Denmark : the SHADE cohort. I: B M C Infectious Diseases. 2016 ; Bind 16.

Bibtex

@article{96818c66ff3f46b6bcc462ce19d67169,
title = "Sexually transmitted infections and use of contraceptives in women living with HIV in Denmark: the SHADE cohort",
abstract = "BACKGROUND: No Danish guidelines for screening of sexually transmitted infections (STIs) in women living with HIV (WLWH) exist, except for annual syphilis testing. Drug-drug interaction between hormonal contraceptives and some types of highly active antiretroviral therapy (HAART) occurs. We assessed prevalence of STIs, contraceptive choices and predictors of condom use in a cohort of WLWH in Denmark.METHODS: WLWH consecutively enrolled during their outpatient visits from 2011 to 2012. Gynaecological examination and an interview were performed at entry and 6-month follow-up. Inclusion criteria were HIV-1 infection and ≥ 18 years of age. Exclusion criteria were pregnancy, alcohol- or drug abuse impeding adherence to the protocol. At entry, participants were tested (and where appropriate, treated according to guidelines) for Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis, and herpes simplex (HSV-1 and HSV-2). At follow-up, predictors of condom use were estimated in sexually active WLWH.RESULTS: In total, 334 of the 1,392 eligible WLWH in Denmark were included (median age and HIV duration: 42.5 and 11.3 years). Chlamydia trachomatis was present in four individuals (1 %), and six (2 %) tested positive for HSV-2 by PCR. None were positive for Neisseria gonorrhoeae, HSV-1 or had active syphilis. At follow-up, 252 (76 %) participated; 168 (70 %) were sexually active. Contraceptives were used by 124 (75 %); condoms were preferred (62 %). Having an HIV-negative partner predicted condom use (adjusted OR 3.89 (95 %CI 1.49-10.11)). In the group of participants of reproductive age without pregnancy desires 13 % used no birth-control. Possible drug-drug interaction between hormonal contraceptives and HAART was found in 13/14 WLWH receiving both kinds of medication.CONCLUSION: The prevalence of STIs in WLWH in Denmark was low. The need for annual STI screening is questionable. Condoms were preferred contraceptives, especially in WLWH with an HIV-negative partner. In this cohort, 13 % of WLWH of reproductive age were at risk of unintended pregnancies due to lack of birth-control. Finally, in the subgroup of WLWH receiving both hormonal contraceptives and HAART possible drug-drug interactions could occur.",
keywords = "Journal Article, Research Support, Non-U.S. Gov't",
author = "Kristina Thorsteinsson and Steen Ladelund and Merete Storgaard and R{\o}nsholt, {Frederikke Falkencrone} and Johansen, {Isik Somuncu} and Gitte Pedersen and Nielsen, {Lars N{\o}rreg{\aa}rd} and Jesper Bonde and Henrik Westh and Niels Obel and Katzenstein, {Terese L} and Anne-Mette Lebech",
year = "2016",
doi = "10.1186/s12879-016-1412-7",
language = "English",
volume = "16",
journal = "B M C Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Sexually transmitted infections and use of contraceptives in women living with HIV in Denmark

T2 - the SHADE cohort

AU - Thorsteinsson, Kristina

AU - Ladelund, Steen

AU - Storgaard, Merete

AU - Rønsholt, Frederikke Falkencrone

AU - Johansen, Isik Somuncu

AU - Pedersen, Gitte

AU - Nielsen, Lars Nørregård

AU - Bonde, Jesper

AU - Westh, Henrik

AU - Obel, Niels

AU - Katzenstein, Terese L

AU - Lebech, Anne-Mette

PY - 2016

Y1 - 2016

N2 - BACKGROUND: No Danish guidelines for screening of sexually transmitted infections (STIs) in women living with HIV (WLWH) exist, except for annual syphilis testing. Drug-drug interaction between hormonal contraceptives and some types of highly active antiretroviral therapy (HAART) occurs. We assessed prevalence of STIs, contraceptive choices and predictors of condom use in a cohort of WLWH in Denmark.METHODS: WLWH consecutively enrolled during their outpatient visits from 2011 to 2012. Gynaecological examination and an interview were performed at entry and 6-month follow-up. Inclusion criteria were HIV-1 infection and ≥ 18 years of age. Exclusion criteria were pregnancy, alcohol- or drug abuse impeding adherence to the protocol. At entry, participants were tested (and where appropriate, treated according to guidelines) for Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis, and herpes simplex (HSV-1 and HSV-2). At follow-up, predictors of condom use were estimated in sexually active WLWH.RESULTS: In total, 334 of the 1,392 eligible WLWH in Denmark were included (median age and HIV duration: 42.5 and 11.3 years). Chlamydia trachomatis was present in four individuals (1 %), and six (2 %) tested positive for HSV-2 by PCR. None were positive for Neisseria gonorrhoeae, HSV-1 or had active syphilis. At follow-up, 252 (76 %) participated; 168 (70 %) were sexually active. Contraceptives were used by 124 (75 %); condoms were preferred (62 %). Having an HIV-negative partner predicted condom use (adjusted OR 3.89 (95 %CI 1.49-10.11)). In the group of participants of reproductive age without pregnancy desires 13 % used no birth-control. Possible drug-drug interaction between hormonal contraceptives and HAART was found in 13/14 WLWH receiving both kinds of medication.CONCLUSION: The prevalence of STIs in WLWH in Denmark was low. The need for annual STI screening is questionable. Condoms were preferred contraceptives, especially in WLWH with an HIV-negative partner. In this cohort, 13 % of WLWH of reproductive age were at risk of unintended pregnancies due to lack of birth-control. Finally, in the subgroup of WLWH receiving both hormonal contraceptives and HAART possible drug-drug interactions could occur.

AB - BACKGROUND: No Danish guidelines for screening of sexually transmitted infections (STIs) in women living with HIV (WLWH) exist, except for annual syphilis testing. Drug-drug interaction between hormonal contraceptives and some types of highly active antiretroviral therapy (HAART) occurs. We assessed prevalence of STIs, contraceptive choices and predictors of condom use in a cohort of WLWH in Denmark.METHODS: WLWH consecutively enrolled during their outpatient visits from 2011 to 2012. Gynaecological examination and an interview were performed at entry and 6-month follow-up. Inclusion criteria were HIV-1 infection and ≥ 18 years of age. Exclusion criteria were pregnancy, alcohol- or drug abuse impeding adherence to the protocol. At entry, participants were tested (and where appropriate, treated according to guidelines) for Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis, and herpes simplex (HSV-1 and HSV-2). At follow-up, predictors of condom use were estimated in sexually active WLWH.RESULTS: In total, 334 of the 1,392 eligible WLWH in Denmark were included (median age and HIV duration: 42.5 and 11.3 years). Chlamydia trachomatis was present in four individuals (1 %), and six (2 %) tested positive for HSV-2 by PCR. None were positive for Neisseria gonorrhoeae, HSV-1 or had active syphilis. At follow-up, 252 (76 %) participated; 168 (70 %) were sexually active. Contraceptives were used by 124 (75 %); condoms were preferred (62 %). Having an HIV-negative partner predicted condom use (adjusted OR 3.89 (95 %CI 1.49-10.11)). In the group of participants of reproductive age without pregnancy desires 13 % used no birth-control. Possible drug-drug interaction between hormonal contraceptives and HAART was found in 13/14 WLWH receiving both kinds of medication.CONCLUSION: The prevalence of STIs in WLWH in Denmark was low. The need for annual STI screening is questionable. Condoms were preferred contraceptives, especially in WLWH with an HIV-negative partner. In this cohort, 13 % of WLWH of reproductive age were at risk of unintended pregnancies due to lack of birth-control. Finally, in the subgroup of WLWH receiving both hormonal contraceptives and HAART possible drug-drug interactions could occur.

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1186/s12879-016-1412-7

DO - 10.1186/s12879-016-1412-7

M3 - Journal article

C2 - 26880101

VL - 16

JO - B M C Infectious Diseases

JF - B M C Infectious Diseases

SN - 1471-2334

M1 - 81

ER -

ID: 165009057